Gradient Investments LLC Boosts Holdings in Eli Lilly and Company $LLY

Key Points

• Gradient Investments increased its Eli Lilly position by 39.6% in the second quarter, bringing its holdings to 27,342 shares valued at approximately $32.8 million. Institutional investors collectively own 82.53% of LLY.
• Lilly reported strong second-quarter results, with revenue up 47.7% year over year to $22.97 billion and EPS of $8.38, beating estimates. Management raised its 2026 revenue guidance to $85 billion-$87 billion, driven by demand for Mounjaro and Zepbound.
• Analysts remain bullish, but valuation risks persist. The stock carries a consensus “Moderate Buy” rating and an average price target of $1,292.18, while shares trade near their 12-month high at about 40 times earnings.

Gradient Investments LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 39.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,342 shares of the company's stock after buying an additional 7,757 shares during the period. Gradient Investments LLC's holdings in Eli Lilly and Company were worth $32,795,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in LLY. Osbon Capital Management LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $25,000. Basso Capital Management L.P. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $30,000. E Fund Management Hong Kong Co. Ltd. raised its holdings in Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock valued at $32,000 after buying an additional 24 shares during the period. New England Capital Financial Advisors LLC raised its holdings in Eli Lilly and Company by 142.9% in the 4th quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company's stock valued at $37,000 after buying an additional 20 shares during the period. Finally, Maseco LLP lifted its position in Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company's stock valued at $31,000 after buying an additional 28 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Beat-and-raise quarter reinforces growth outlook. Lilly reported second-quarter revenue of approximately $22.97 billion and EPS of $8.38, exceeding consensus estimates. Revenue increased 47.7% year over year, and management raised 2026 revenue guidance to $85 billion-$87 billion from $82 billion-$85 billion, primarily because of strong demand for its diabetes and obesity medicines. Eli Lilly raises 2026 outlook again as Q2 soars past estimates
• Positive Sentiment: Weight-loss portfolio continues to drive investor enthusiasm. Mounjaro sales rose 91%, while Mounjaro and Zepbound together generated nearly $15 billion, widening Lilly’s lead over Novo Nordisk. Foundayo adoption is also gaining traction, Medicare access is expanding, and retatrutide is progressing toward a potential 2027 regulatory filing. LLY Q2 Earnings Call Raises Outlook as Foundayo Gains Traction
• Positive Sentiment: Analysts remain bullish. Truist raised its price target to $1,376 and maintained a Buy rating, while Cantor Fitzgerald lifted its target to $1,410 with an Overweight rating. Analysts cited durable incretin demand and the stronger long-term growth outlook. Eli Lilly’s Incretin Performance Supports Long-Term Growth
• Positive Sentiment: Favorable legal news removes a potential overhang. Lilly and Novo Nordisk defeated an antitrust lawsuit concerning the GLP-1 drug market, reducing near-term litigation risk. Lilly, Novo defeat antitrust lawsuit over GLP-1 drug market
• Neutral Sentiment: Retatrutide is being offered to some patients before FDA approval. Early access could generate real-world experience and strengthen demand, but the treatment remains subject to regulatory approval and related safety scrutiny. Eli Lilly offers new weight loss drug to some patients before FDA approval
• Negative Sentiment: Profit-taking and valuation concerns may be limiting the response. Following the earnings-driven advance, Lilly trades at roughly 40 times earnings and near its record high. Investors may be demanding continued execution, while expanding access through Amazon and competing obesity drugs could increase pricing and market-share pressure.

Wall Street Analyst Weigh In

LLY has been the subject of a number of recent analyst reports. Wolfe Research reiterated an "outperform" rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Rothschild & Co Redburn boosted their price target on shares of Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. The Goldman Sachs Group restated a "buy" rating and issued a $1,283.00 price objective on shares of Eli Lilly and Company in a report on Friday, May 22nd. Guggenheim increased their price objective on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a "buy" rating in a research report on Monday, July 13th. Finally, Morgan Stanley reiterated an "overweight" rating and issued a $1,419.00 target price on shares of Eli Lilly and Company in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $1,292.18.

Eli Lilly and Company Stock Down 0.4%

Shares of NYSE LLY opened at $1,186.71 on Friday. The stock has a market cap of $1.12 trillion, a P/E ratio of 39.82, a PEG ratio of 1.38 and a beta of 0.51. The business's fifty day simple moving average is $1,159.38 and its 200-day simple moving average is $1,047.55. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,249.45. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm had revenue of $22.97 billion during the quarter, compared to analysts' expectations of $20.82 billion. During the same period in the previous year, the firm posted $6.31 EPS. Eli Lilly and Company's revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 37.55 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company's payout ratio is currently 23.22%.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source